

## Letter to the Editor

# Earlier onset of treatment improves the nephroprotective effect of dapagliflozin



## El inicio temprano del tratamiento mejora el efecto nefroprotector con dapagliflozina

Dear Editor,

Chronic kidney disease (CKD) is a common condition that is a major risk factor for cardio-vascular events, end-stage renal disease and all-cause mortality.<sup>1</sup> In several large trials, dapagliflozin treatment reduced both primary and secondary renal outcomes at different levels of estimated glomerular filtration rate (eGFR). Dapagliflozin reduced the rate of eGFR decline over time, one of the secondary renal outcomes.<sup>2-5</sup>

Glomerular hyperfiltration plays a key role in the progression of CKD, causing intraglomerular hypertension, inflammatory changes, extracellular matrix accumulation and podocyte injury. In addition, loss of eGFR causes compensatory hyperfiltration in the remaining nephrons, leading


to further decline in eGFR through glomerulosclerosis and tubulointerstitial fibrosis. Sodium-glucose linked transporter type 2 (SGLT-2) inhibitors are associated with a reduction in glomerular hyperfiltration, probably due to an increase in pre-glomerular vasoconstriction and a decrease in postglomerular vascular resistance.<sup>6</sup>

We therefore investigated whether the efficacy of dapagliflozin in slowing the progression of eGFR decline would be influenced by the degree of renal function. A well-known phenomenon observed in studies performed with SGLT-2 inhibitors is a more pronounced fall of the eGFR in treated groups than in PBO groups during the first weeks of treatment (acute phase). This was followed by a partial recovery and thereafter a persistent lower decline of the

**Table 1 – Differences between DAPA and PBO groups in time lapse (years) from eGFR at onset of chronic phase to ESKD.**

Studies	eGFR at onset of chronic phase	eGFR reserve to ESKD	eGFR decline per year in chronic phase	eGFR decline per year in chronic phase PBO-DAPA	Time to ESKD differences DAPA vs. PBO
<i>DECLARE-TIMI 58 kidney disease prevention post hoc analyses<sup>8</sup></i>					
DAPA	82.41	67.41	1.54	1.01	68.27
PBO	83.95	68.95	2.55		
<i>DAPA-HF renal function outcomes<sup>9</sup></i>					
DAPA	61.81	46.81	1.09	1.76	28.07
PBO	64.41	49.41	2.85		
<i>DAPA-CKD prespecified analysis<sup>4</sup> eGFR &gt; 45</i>					
DAPA	51.80	36.80	1.99	2.14	18.27
PBO	54.10	39.10	4.13		
<i>DAPA-CKD prespecified analysis<sup>4</sup> eGFR &lt; 45</i>					
DAPA	32.10	17.10	1.48	1.74	10.8
PBO	33.80	18.80	3.22		
<i>DELIVER kidney outcomes prespecified analysis<sup>7</sup></i>					
DAPA	57.3	42.3	0	1.4	32.57
PBO	60.6	45.6	1.4		

Data taken from referred studies. eGFR: estimated glomerular filtration rate (ml/min/1.73m<sup>2</sup>); ESKD: end stage kidney disease; DAPA: dapagliflozin; PBO: placebo.



**Fig. 1 – Correlation between eGFR at onset of chronic phase and differences in time lapse (years) from onset of chronic phase to ESKD. Data taken from referred studies. eGFR: estimated glomerular filtration rate (ml/min/1.73 m<sup>2</sup>); ESKD: end stage kidney disease; DAPA: dapagliflozin; PBO: placebo.**

eGFR until the end of the follow-up period (chronic phase) in treated groups. Thus, for the present analysis we took data from several published studies<sup>4,7-9</sup> to evaluate the possible existence of a correlation between eGFR at the onset of chronic phase and differences in time to end stage kidney disease (ESKD). The eGFR reserve to ESKD was calculated as eGFR at onset of chronic phase minus 15. The difference in time to ESKD induced by dapagliflozin intervention was calculated by dividing the eGFR reserve to ESKD in the placebo group by the PBO-DAPA difference in eGFR decline per year during the chronic phase (Table 1). As a result, we found a significant correlation between these two parameters (Rho Spearman 0.90;  $p=0.0374$ ) (Fig. 1).

In view of this finding, we believe that it is reasonable to conclude that the nephroprotective effect of dapagliflozin could be related to the degree of renal function. It could be said that from a mechanistic point of view this is not an unexpected finding, since the smaller the mass of functioning nephrons, the fewer the number of points at which the drug can exert its mechanism of action. This may have broad applicability in the clinical setting because although dapagliflozin could delay the disease progression at any stage of CKD, the earlier treatment is established the longer the patient will remain in a less unfavourable clinical condition. Thus, the early initiation of treatment is of particular interest, not only because of its clinical relevance, but also because it can result in substantial cost savings both in terms of reduced pharmaceutical costs and a smaller number of patients on renal replacement therapy.

### Conflict of interest

Antonio Gippini has received fees for presentations and advisory boards from Amgen, AstraZeneca, Boehringer-Ingelheim, Esteve, Ferrer, Janssen, Lilly, Mundipharma, Mylan, Novartis and NovoNordisk.

Alberto Prado works in Cardiovascular Renal and Metabolism (CVRM) Medical Department of AstraZeneca, Spain.

### REFERENCES

- García-Maset R, Bovera J, Segura J, Goicoechea M, Cebollada J, Escalada J, et al. Documento de información y consenso para la detección y manejo de la enfermedad renal crónica. *Nefrología*. 2022;42:223–362.
- Wiviott S, Raz M, Bonaca O, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2019;380:347–57.
- McMurray J, Solomon S, Inzucchi S, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. *N Engl J Med*. 2019;381:1995–2008.
- Heerspink H, Jongs N, Chertow G, Langkilde AM, McMurray JJV, Correa-Rotter R, et al. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from DAPA-CKD trial. *Lancet Diabetes Endocrinol*. 2021;9:743–54.
- Solomon S, McMurray J, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. *N Engl J Med*. 2022;387:1089–98.
- van Bommel EJM, Muskiet MHA, van Baar MJB, Tonneijck L, Smits MM, Emanuel AL, et al. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by postglomerular vasodilatation rather than preglomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. *Kidney Int*. 2020;97:202–12.
- Causland F, Claggett B, Vaduganathan M, Desai AS, Jhund P, de Boer RA, et al. Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction. A prespecified analysis of the DELIVER randomized clinical trial. *JAMA Cardiol*. 2023;8:56–65.

8. Mosenzon O, Raz I, Wiviott S, Schechter M, Goodrich EL, Yanuv I, et al. Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes: post hoc analyses from the DECLARE-TIMI 58 trial. *Diabetes Care*. 2022;45:2350-9.
9. Jhund P, Solomon S, Docherty K. Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction. *Results of DAPA-HF*. *Circulation*. 2021;143:298-309.

Antonio Gippini<sup>a,\*</sup>, Alberto Prado<sup>b</sup>

<sup>a</sup> Endocrinologist, Endocrinology Service, Hospitalary Complex Ourense, National Health System, Spain

<sup>b</sup> Pharmacist, Master in Statistics, Cardiovascular Renal Metabolism (CVRM), Medical Department, AstraZeneca, Spain

\* Corresponding author.

E-mail address: [agippiniperez@gmail.com](mailto:agippiniperez@gmail.com) (A. Gippini).

0211-6995/© 2023 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

<https://doi.org/10.1016/j.nefro.2023.05.005>

## Experiencia en vida real con terapias frente a COVID-19 leve-moderada en trasplantados renales: ¿cómo tratar a partir de ahora a los pacientes con enfermedad renal crónica?

### Real-world experience with mild-moderate COVID-19 therapies in kidney transplant patients: How to treat patients with chronic kidney disease from now on?



Sr. Director,

En los últimos meses, las recomendaciones para el tratamiento de pacientes no hospitalizados con COVID-19 leve-moderada con alto riesgo de progresión a enfermedad grave incluían varios fármacos antivirales (nirmatrelvir/ritonavir, remdesivir y molnupiravir) y anticuerpos monoclonales (mAB) (fundamentalmente sotrovimab en Europa)<sup>1</sup>. Sin embargo, hay poco documentado sobre su eficacia en vida real en receptores de trasplante renal (TR)<sup>2,3</sup>.

Realizamos un estudio de cohortes retrospectivo de todos los TR con COVID-19 leve-moderada durante el periodo del 1 de enero de 2022 al 31 de diciembre de 2022 que recibieron tratamiento ambulatorio en nuestra área hospitalaria. Definimos COVID-19 leve-moderada cuando los pacientes presentaban síntomas relacionados con la infección por SARS-CoV-2 (diagnosticada por PCR y/o antígeno) sin indicación de ingreso hospitalario. Consideramos progresión a COVID-19 grave cuando los pacientes requirieron hospitalización y/o fallecieron. La indicación de tratamiento farmacológico se realizó según factores de riesgo conocidos de progresión de la enfermedad: edad >60 años y/o tiempo post-TR <2 años y/o comorbilidades. La elección del fármaco dependió de los títulos de IgG anti-S (<1.000 BAU/ml: sotrovimab) y del filtrado glomerular estimado (FGe) (>30 ml/min/1,73 m<sup>2</sup>: remdesivir en pauta de 3 días; <30 ml/min/1,73 m<sup>2</sup>: molnupiravir). No consideramos utilizar nirmatrelvir/ritonavir debido a las fuertes interacciones farmacológicas descritas con los fármacos inmunosupresores. Por otro lado, recogimos datos de todos los pacientes TR que requirieron hospitalización por

COVID-19 durante el periodo del estudio, tanto los tratados como los no tratados antes del ingreso, como grupo de comparación.

Durante 2022, 107 TR con COVID-19 leve-moderada recibieron tratamiento ambulatorio (sotrovimab n=63, remdesivir n=34, molnupiravir n=10) (tabla 1). El 83,8% estaban vacunados según la pauta indicada por el Ministerio de Sanidad en el momento de la infección. No había diferencias en las características de los pacientes ni en las manifestaciones clínicas según el fármaco recibido, salvo en los criterios de indicación de cada fármaco (función renal, IgG anti-S).

Por otro lado, 37 TR fueron hospitalizados a lo largo del año por COVID-19. Solo 3 de ellos habían recibido tratamiento ambulatorio previamente (sotrovimab n=2, molnupiravir n=1); el resto no contactaron previamente con la consulta de TR y ya presentaban COVID-19 grave cuando acudieron al hospital, precisando ingreso. Al comparar los factores de riesgo reconocidos para la progresión a COVID-19 grave, no encontramos diferencias entre los dos grupos, tratados y no tratados de forma ambulatoria (tabla 2). Cinco pacientes fallecieron, todos ellos del grupo que no había recibido tratamiento ambulatorio.

Presentamos la serie más extensa de pacientes TR con COVID-19 leve-moderada tratados de forma ambulatoria. Nuestros resultados sugieren que las terapias anti-COVID-19 en fase temprana pueden detener la progresión a enfermedad grave en pacientes de alto riesgo. Muy pocos pacientes de los tratados ambulatoriamente precisaron ingreso y ninguno falleció. Los pacientes ingresados sin tratamiento previo